GlassScriptPhysician profile
Jesse Dinh Le
NPI 1457679201
$7,651.63
in general payments reported to CMS, 2019-2025
47 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $686 · 2021: $678 · 2022: $1,249 · 2023: $1,695 · 2024: $1,166 · 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,174 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.80 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.02 | 2019-2025 | |
| Janssen Biotech, INC. | $826.19 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $618.54 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $590.21 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $523.36 | 2023-2025 | Gemtesa, Orgovyx |
| Urogen Pharma, INC. | $452.58 | 2020-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $324.45 | 2019-2025 | Adstiladrin, Menopur |
| Astrazeneca Pharmaceuticals LP | $305.65 | 2023-2025 | Lynparza |
| Myovant Sciences INC. | $246.22 | 2021-2022 | |
| Urovant Sciences INC | $239.30 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $227.94 | 2019-2025 | |
| Amgen INC. | $224.51 | 2019-2023 | Xgeva |
| Endo Pharmaceuticals INC. | $202.11 | 2019-2023 | Xiaflex, Aveed |
| Dornier Medtech America, INC | $187.79 | 2020-2023 | Dornier Medtech |
| Myriad Genetic Laboratories, INC. | $180.54 | 2021-2024 | Prolaris, Myrisk |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $164.08 | 2019-2024 | Porges Coloplast |
| Merck Sharp & Dohme LLC | $148.98 | 2022-2025 | Lynparza, Keytruda, Zerbaxa |
| Ambu INC. | $142.47 | 2024-2025 | |
| Smith+Nephew, INC. | $137.87 | 2022 | |
| Allergan, INC. | $133.14 | 2019-2021 | |
| Boston Scientific Corporation | $98.78 | 2020-2024 | Spaceoar System, Rezum Generator |
| Blue Earth Diagnostics | $85.51 | 2019-2024 | |
| Procept Biorobotics Corporation | $78.79 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Immunitybio, INC. | $66.59 | 2024 | |
| Travere Therapeutics, INC. | $54.95 | 2020-2022 | |
| Teleflex LLC | $50.64 | 2022-2024 | Quikclot |
| Olympus America INC. | $37.06 | 2020 | |
| Antares Pharma, INC. | $32.06 | 2021-2022 | |
| Bluewind Medical | $28.66 | 2024 | Revi |
| Sagent Pharmaceuticals | $28.53 | 2022 | |
| 180 Medical, INC. | $26.05 | 2019 | |
| Seagen INC. | $25.47 | 2019 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $22.85 | 2020 | |
| Emd Serono, INC. | $21.73 | 2023 | Bavencio |
| Alnylam Pharmaceuticals INC. | $20.34 | 2022 | |
| Medtronic, INC. | $18.29 | 2021 | |
| Therapeuticsmd, INC. | $18.13 | 2021 | |
| Acacia Pharma INC | $17.00 | 2022 | |
| Karl Storz Endoscopy-America | $16.67 | 2024 | N.A. |
| Verity Pharmaceuticals INC. | $16.48 | 2024 | Tlando |
| Accord Healthcare, INC. | $16.16 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $15.79 | 2019 | |
| Avanos Medical | $14.79 | 2022 | |
| Abc Home Medical Supply, INC. | $14.43 | 2025 | |
| Photocure INC | $13.21 | 2019 | |
| Dentsply Ih INC. | $12.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.